Phospholipase C-β1 and schizophrenia-related behaviors

Advances in Biological Regulation

Volumn 53, Issue 3, 2013, Pages 242-248

  Koh, Hae Young ^a  

^a Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

PHOSPHOLIPASE C BETA;

ANIMAL; BEHAVIOR; BRAIN; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOUSE; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA;

ANIMALS; BEHAVIOR; BRAIN; HUMANS; MICE; PHOSPHOLIPASE C BETA; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84885694702     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.08.002     Document Type: Review

References (74)

1. Alheid G.F., Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience 1988, 27:1-39.
2. Arinami T., Ohtsuki T., Ishiguro H., Ujike H., Tanaka Y., Morita Y., et al. Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet 2005, 77:937-944.
3. Arakawa H., Arakawa K., Deak T. Oxytocin and vasopressin in the medial amygdala differentially modulate approach and avoidance behavior toward illness-related social odor. Neuroscience 2010, 171:1141-1151.
4. Brennan P.A., Zufall F. Pheromonal communication in vertebrates. Nature 2006, 444:308-315.
5. Brody S.A., Dulawa S.C., Conquet F., Geyer M.A. Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 2004, 9:35-41.
6. Carlsson A. A paradigm shift in brain research. Science 2001, 294:1021-1024.
7. Choleris E., Little S.R., Mong J.A., Puram S.V., Langer R., Pfaff D.W. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. Proc Natl Acad Sci USA 2007, 104:4670-4675.
8. Creese I., Iversen S.D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 1975, 83:419-436.
9. Dash P.K., Moore A.N., Kobori N., Runyan J.D. Molecular activity underlying working memory. Learn Mem 2007, 14:554-563.
10. Drevets W.C., Gautier C., Price J.C., Kupfer D.J., Kinahan P.E., Grace A.A., et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001, 49:81-96.
11. Dufour B.D., Garner J.P. An ethological analysis of barbering behavior. Neurobiology of grooming behavior 2010, 184-225. Cambridge University Press, UK. A.V. Kalueff, J.L. LaPorte, C.L. Bergner (Eds.).
12. Dulawa S.C., Geyer M.A. Psychopharmacology of prepulse inhibition in mice. Chin J Physiol 1996, 39:139-146.
13. Egashira N., Tanoue A., Higashihara F., Fuchigami H., Sano K., Mishima K., et al. Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2005, 30:1996-2005.
14. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000, 14:1-21.
15. Feifel D., Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl) 1999, 141:93-98.
16. Feifel D., Shilling P.D., Belcher A.M. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol The J Eur Coll Neuropsychopharmacol 2012, 22:374-378.
17. Ferguson J.N., Aldag J.M., Insel T.R., Young L.J. Oxytocin in the medial amygdala is essential for social recognition in the mouse. J Neurosci 2001, 21:8278-8285.
18. Fukaya M., Uchigashima M., Nomura S., Hasegawa Y., Kikuchi H., Watanabe M. Predominant expression of phospholipase Cbeta1 in telencephalic principal neurons and cerebellar interneurons, and its close association with related signaling molecules in somatodendritic neuronal elements. Eur J Neurosci 2008, 28:1744-1759.
19. Gao W.J., Goldman-Rakic P.S. NMDA receptor-mediated epileptiform persistent activity requires calcium release from intracellular stores in prefrontal neurons. Exp Neurol 2006, 197:495-504.
20. Gerber D.J., Sotnikova T.D., Gainetdinov R.R., Huang S.Y., Caron M.G., Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001, 98:15312-15317.
21. Gerfen C.R. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 1984, 311:461-464.
22. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001, 81:629-683.
23. Gurling H.M., Kalsi G., Brynjolfson J., Sigmundsson T., Sherrington R., Mankoo B.S., et al. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet 2001, 68:661-673.
24. Gutkind J.S., Novotny E.A., Brann M.R., Robbins K.C. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA 1991, 88:4703-4707.
25. Khan Z.U., Muly E.C. Molecular mechanisms of working memory. Behav Brain Res 2011, 219:329-341.
26. Khan Z.U., Muly E.C. Molecular mechanisms of working memory. Behav Brain Res 2011, 219:329-341.
27. Kinney G.G., Burno M., Campbell U.C., Hernandez L.M., Rodriguez D., Bristow L.J., et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 2003, 306:116-123.
28. Knobloch H.S., Charlet A., Hoffmann L.C., Eliava M., Khrulev S., Cetin A.H., et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron 2012, 73:553-566.
29. Koch M., Bubser M. Deficient sensorimotor gating after 6-hydroxydopamine lesion of the rat medial prefrontal cortex is reversed by haloperidol. Eur J Neurosci 1994, 6:1837-1845.
30. Koh H.Y., Kim D., Lee J., Lee S., Shin H.S. Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1. Genes Brain Behav 2008, 7:120-128.
31. Koh H.Y., Kim H.J. Abnormal maternal behavior in mice lacking phospholipase Cß1 2012, 137.09. FENS Forum Abstracts Barcelona: Federation of European Neuroscience Societies.
32. Kohl S., Heekeren K., Klosterkotter J., Kuhn J. Prepulse inhibition in psychiatric disorders-apart from schizophrenia. J Psychiatr Res 2013, 47:445-452.
33. Lee H.J., Caldwell H.K., Macbeth A.H., Tolu S.G., Young W.S. A conditional knockout mouse line of the oxytocin receptor. Endocrinology 2008, 149:3256-3263.
34. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2005, 30:1883-1894.
35. Lin X.H., Kitamura N., Hashimoto T., Shirakawa O., Maeda K. Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia. Biol Psychiatry 1999, 46:1665-1671.
36. Linn G.S., Javitt D.C. Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 2001, 12:117-120.
37. Long J.M., LaPorte P., Paylor R., Wynshaw-Boris A. Expanded characterization of the social interaction abnormalities in mice lacking Dvl1. Genes Brain Behav 2004, 3:51-62.
38. Lopez-Tellez J.F., Lopez-Aranda M.F., Navarro-Lobato I., Masmudi-Martin M., Montanez E.M., Calvo E.B., et al. Prefrontal inositol triphosphate is molecular correlate of working memory in nonhuman primates. J Neurosci 2010, 30:3067-3071.
39. Macdonald K., Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatrica: Officieel Wetenschappelijk Orgaan Van Het IGBP 2012, 24:130-146.
40. Macdonald K., Feifel D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front Neurosci 2013, 7:35.
41. Manning M., Misicka A., Olma A., Bankowski K., Stoev S., Chini B., et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012, 24:609-628.
42. McCall C., Singer T. The animal and human neuroendocrinology of social cognition, motivation and behavior. Nat Neurosci 2012, 15:681-688.
43. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961, 34:103-116.
44. McOmish C.E., Burrows E., Howard M., Scarr E., Kim D., Shin H.S., et al. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol Psychiatry 2008, 13:661-672.
45. McOmish C.E., Burrows E.L., Howard M., Hannan A.J. PLC-beta1 knockout mice as a model of disrupted cortical development and plasticity: behavioral endophenotypes and dysregulation of RGS4 gene expression. Hippocampus 2008, 18:824-834.
46. Miyakawa T., Yamada M., Duttaroy A., Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 2001, 21:5239-5250.
47. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., et al. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr Res 2011, 132:50-53.
48. Pietraszek M., Nagel J., Gravius A., Schafer D., Danysz W. The role of group I metabotropic glutamate receptors in schizophrenia. Amino Acids 2007, 32:173-178.
49. Pobbe R.L., Pearson B.L., Defensor E.B., Bolivar V.J., Young W.S., Lee H.J., et al. Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors. Horm Behav 2012, 61:436-444.
50. Rhee S.G., Bae Y.S. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem 1997, 272:15045-15048.
51. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res 2010, 124:13-21.
52. Runyan J.D., Moore A.N., Dash P.K. A role for prefrontal calcium-sensitive protein phosphatase and kinase activities in working memory. Learn Mem 2005, 12:103-110.
53. Sala M., Braida D., Donzelli A., Martucci R., Busnelli M., Bulgheroni E., et al. Mice heterozygous for the oxytocin receptor gene (Oxtr(+/-)) show impaired social behaviour but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect. J Neuroendocrinol 2013, 25:107-118.
54. Sasayama D., Hattori K., Teraishi T., Hori H., Ota M., Yoshida S., et al. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res 2012, 139:201-206.
55. Schwabe K., Koch M. Role of the medial prefrontal cortex in N-methyl-D-aspartate receptor antagonist induced sensorimotor gating deficit in rats. Neurosci Lett 2004, 355:5-8.
56. Shin H.S., Kim D., Koh H.Y. Lack of barbering behavior in the phospholipase Cβ1 mutant mouse: a model animal for schizophrenia. Neurobiology of grooming behavior 2010, 131-144. Cambridge University Press, UK.
57. Shin J., Kim D., Bianchi R., Wong R.K., Shin H.S. Genetic dissection of theta rhythm heterogeneity in mice. Proc Natl Acad Sci USA 2005, 102:18165-18170.
58. Shirakawa O., Kitamura N., Lin X.H., Hashimoto T., Maeda K. Abnormal neurochemical asymmetry in the temporal lobe of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:867-877.
59. Strozik E., Festing M.F. Whisker trimming in mice. Lab Anim 1981, 15:309-312.
60. Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron 2012, 76:142-159.
61. Swanson L.W., Petrovich G.D. What is the amygdala?. Trends Neurosci 1998, 21:323-331.
62. Swerdlow N., Geyer M., Braff D. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156:194-215.
63. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 2008, 199:331-388.
64. Thomsen M., Wortwein G., Fink-Jensen A., Woldbye D.P., Wess J., Caine S.B. Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berl) 2007, 192:97-110.
65. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23:583-592.
66. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007, 33:69-94.
67. Udawela M., Scarr E., Hannan A.J., Thomas E.A., Dean B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry 2011, 45:140-147.
68. Ukai M., Okuda A., Mamiya T. Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice. Eur J Pharmacol 2004, 492:183-187.
69. Veinante P., Freund-Mercier M.J. Distribution of oxytocin- and vasopressin-binding sites in the rat extended amygdala: a histoautoradiographic study. J Comp Neurol 1997, 383:305-325.
70. Venables P.H. Input dysfunction in schizophrenia. Prog Exp Pers Res 1964, 72:1-47.
71. Wang H., Ng K., Hayes D., Gao X., Forster G., Blaha C., et al. Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2004, 29:2126-2139.
72. Watanabe M., Nakamura M., Sato K., Kano M., Simon M.I., Inoue Y. Patterns of expression for the mRNA corresponding to the four isoforms of phospholipase Cbeta in mouse brain. Eur J Neurosci 1998, 10:2016-2025.
73. Winslow J.T., Insel T.R. The social deficits of the oxytocin knockout mouse. Neuropeptides 2002, 36:221-229.
74. Yamada M., Miyakawa T., Duttaroy A., Yamanaka A., Moriguchi T., Makita R., et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001, 410:207-212.